Emtricitabine News and Research

RSS
Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Indonesia to issue compulsory licenses for HIV, hepatitis B drugs still under patent

Indonesia to issue compulsory licenses for HIV, hepatitis B drugs still under patent

Study finds antiretroviral-based strategies to prevent HIV infection among women prove ineffective

Study finds antiretroviral-based strategies to prevent HIV infection among women prove ineffective

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead commences first of two tenofovir alafenamide Phase 3 trials in HIV

Gilead commences first of two tenofovir alafenamide Phase 3 trials in HIV

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen announces U.S. prescribing information update for EDURANT tablets

IQWiG investigates benefits of rilpivirine for HIV treatment

IQWiG investigates benefits of rilpivirine for HIV treatment

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

FDA approves Gilead’s Stribild to treat HIV-1 infection

FDA approves Gilead’s Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences signs deals with 3 Indian pharmaceutical companies to promote low-cost HIV drugs in developing countries

Gilead Sciences signs deals with 3 Indian pharmaceutical companies to promote low-cost HIV drugs in developing countries

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Dapivirine Phase III trial now underway in Africa to treat HIV in women

Dapivirine Phase III trial now underway in Africa to treat HIV in women

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

All adult patients with HIV should be offered ART: International Antiviral Society-USA panel

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Truvada gains FDA approval as HIV preventive

Truvada gains FDA approval as HIV preventive

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection